Breaking News
May 20, 2018 - Developmental psychotherapy aims at helping antisocial adolescents become responsible adults
May 20, 2018 - People with OCD process emotions differently than their unaffected siblings
May 20, 2018 - Interfering with enzyme’s movement may be new approach for developing of anti-cancer drugs
May 20, 2018 - Prestroke and poststroke oral anticoagulation therapy in AF patients
May 20, 2018 - Why drug users prefer heroin at home, but cocaine while out
May 20, 2018 - Gene therapy that reverses blindness in dogs could also help treat humans
May 20, 2018 - Opioid-Related Payments Linked to Increase in Opioid Rx
May 20, 2018 - Phone apps push people to take their pills
May 20, 2018 - Backbreaking Work May Shorten Men’s Lives
May 20, 2018 - Harsher drug laws won’t stop violence, argues former police chief
May 20, 2018 - Cognitive decline in dementia is not reduced by exercise
May 20, 2018 - Detecting breast cancer with non-invasive ‘disease screening pill’
May 20, 2018 - Simple treatment may minimize hearing loss triggered by loud noises
May 20, 2018 - Alignment of mother and offspring body clock could prevent diseases such as heart disease and obesity
May 20, 2018 - New commercial data warehouse for life sciences
May 20, 2018 - Practice Intervention Targeting IV Opioids May Cut Exposure
May 20, 2018 - New study provides insight into blood signatures of inflammation
May 20, 2018 - Scientists make breakthrough discovery about vitamin B12
May 20, 2018 - What Causes Cancer? Misconceptions Abound
May 20, 2018 - Proper burial of dead cells limits inflammation
May 20, 2018 - Study offers novel solution to suppress metastatic spread of deadly breast cancer
May 20, 2018 - Perspectives of patients and caregivers on care transitions
May 20, 2018 - Guidelines for weight gain in pregnancy should be changed for underweight and very obese women
May 20, 2018 - Researchers transplant retinal sheets derived from human embryonic stem cells in retinal degeneration mouse models
May 20, 2018 - U.S. military personnel at greater risk for skin cancer than general population
May 20, 2018 - Your immune system holds the line against repeat invaders, thanks to this molecule
May 20, 2018 - Between death and deportation
May 20, 2018 - Developing a High Throughput Mass Spectrometry Platform for Drug Discovery
May 19, 2018 - New project aims to increase awareness among hospital clinicians of non-beneficial treatment at end-of-life
May 19, 2018 - Automated bone scan index offers accurate, speedy prognostic information about prostate cancer
May 19, 2018 - Rutgers Cancer Institute nurses research various topics to enhance patient experience
May 19, 2018 - Computer models provide valuable insight to structure and function of Ebola, Zika viruses
May 19, 2018 - Study exposes key tactic used by deadly fungus
May 19, 2018 - Bacterial signals are crucial to development of pre-leukemic myeloproliferation, study shows
May 19, 2018 - Global experts identify key issues in supporting children with brain injuries transition back to school
May 19, 2018 - Social connections may protect black men who have sex with men from acquiring HIV
May 19, 2018 - Study IDs Factors Linked to Quality of Life With Dementia
May 19, 2018 - Potassium — Consumer
May 19, 2018 - HIV-1 viruses transmitted at birth are resistant to antibodies in mother’s blood
May 19, 2018 - Some water pitchers are much better at removing toxins, shows research
May 19, 2018 - Scientists discover how unusually long strands of RNA help colon cancer cells avoid death
May 19, 2018 - International study finds viable treatment option for people with mild asthma
May 19, 2018 - Mayo discovery could enable development of personalized ovarian, brain cancer treatments
May 19, 2018 - ‘Superbug’ Surfaces at Poultry Farm in China
May 19, 2018 - UCLA-designed program helps former HIV-positive inmates maintain health after release from jail
May 19, 2018 - New blood test could help avoid more than 40% of prostate biopsies, study finds
May 19, 2018 - Macrophages play key role in maintaining stem cell niche of mammary gland
May 19, 2018 - Ferritin Blood Test: MedlinePlus Lab Test Information
May 19, 2018 - Prolonged exposure to air pollution leads to genetic changes in rat brains, study finds
May 19, 2018 - Scientists identify new potential target to combat acute myeloid leukemia
May 19, 2018 - Ovarian cancer therapy may help treat patients with aggressive pancreatic cancer
May 19, 2018 - MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma
May 19, 2018 - Research shows that sexual activity and emotional closeness are unrelated to the rate of cognitive decline
May 19, 2018 - Nuffield Council on Bioethics outlines ethical issues arising from use of AI in healthcare
May 19, 2018 - Pancreatic cancer patients with BRCA1 or BRCA2 mutations fare better on platinum-based chemotherapy
May 19, 2018 - Tradeshow Talks with nal von minden Ltd
May 19, 2018 - Chemist begins new project to develop carbohydrate mimics to assist cancer therapies
May 19, 2018 - Healthy Lifestyle for Healthy Older Adults
May 19, 2018 - Epstein-Barr virus linked to seven serious diseases
May 19, 2018 - Biochemists isolate protein supercomplex from bacteria that generates voltage
May 19, 2018 - Mindfulness-based Stress Management Course for cancer survivors
May 19, 2018 - Simple screening tool can help identify people at increased risk for dementia
May 19, 2018 - Many gay and bisexual teenage boys use adult hookup apps to connect with friends, partners
May 19, 2018 - Maternal Exposure to Polluted Air Tied to Elevated Child BP
May 19, 2018 - Experimental drug extends survival in progeria
May 19, 2018 - FutureNeuro and GreenLight Medicines team up to develop cannabis-based treatments for epilepsies
May 19, 2018 - Brazilians with less education more likely to perceive as being in poor health
May 19, 2018 - Experts available to discuss subjects related to Ebola virus
May 19, 2018 - Opioid Makers’ Perks to Docs Tied to More Prescriptions
May 19, 2018 - AI detects patterns of gut microbes for cholera risk
May 19, 2018 - Researcher develops small molecules that inhibit derailment of gene expression in cancer
May 19, 2018 - Study brings fresh insights into biology of malaria parasite
May 19, 2018 - Microglia may play key role in slowing progression of prion diseases, research suggests
May 19, 2018 - Safety program successfully reduces SSIs in patients undergoing colorectal operations
May 19, 2018 - Clinical study supports usual medical care plus chiropractic care for low back pain
May 19, 2018 - Vermont legislators pass a drug importation law. So what?
May 19, 2018 - Trump proposes cutting planned parenthood funds. What does that mean?
May 19, 2018 - Cognitive training intervention reduces gait freezing in Parkinson’s patients, study shows
May 19, 2018 - Clinical trial begins enrollment to test safety of experimental MERS treatments
May 19, 2018 - Scientists disrupt two enzymes to shrink cancer cells
A Noteworthy Margin of Error

A Noteworthy Margin of Error

image_pdfDownload PDFimage_print

Dermatologists need to be aware of margin of error and related issues that can affect the results of biosimilar clinical trials. Sample size, study population variability, study site geography, and clinical expertise can impact trial results.

The statistical margin used to define the maximum allowable difference between biosimilar and a reference agent for psoriasis may be “unacceptably wide” to some prescribing clinicians, authors of a recent meta-analysis have concluded.

The margin of error, sometimes referred to as the similarity margin, is decided upon by regulatory bodies and may be too imprecise depending on the clinician’s perspective, the authors said in a research letter published recently in the Journal of the American Academy of Dermatology.

For example, if a study’s margin of error is ±15% and the originator biological product has a PASI 75 response rate of 65%, a biosimilar with a PASI 75 of just 50% could be deemed equivalent, according to Marilyn T. Wan, MBChB, MPH, of the University of Pennsylvania Perelman School of Medicine, Philadelphia, and co-authors.

“One physician might consider these parameters sufficient and comfortably prescribe the biosimilar as a replacement for the originator; however, another clinician might require more conservative margins,” Wan and colleagues said in the research letter.

Authors based their comments on a systematic review of statistical margins in comparative clinical trials of biosimilars. They considered trials published through Feb. 17, 2017, and sought data from unpublished or unidentified studies. The studies they selected included adult patients with plaque psoriasis who were randomly assigned to receive a biosimilar or originator drug.

They narrowed the search to four clinical trials including 1,746 patients, which had margins of error ranging from ±14% to ±18%, the meta-analysis showed.

Another five clinical trials were excluded, according to the report, due to data that was insufficient and not obtainable through subsequent requests sent to corresponding authors.

“As biosimilar approvals accrue and their use increases, possibly delivering decreased healthcare costs and better patient access, practitioners require a deeper understanding of the design and conduct of clinical trials to better interpret the true likelihood of achieving the same clinical outcome regardless of drug choice,” authors of the meta-analysis wrote.

Biosimilar study goals

Biosimilars are typically investigated in equivalence trials designed to show the drug is not too different (ie., not superior or inferior) in comparison to the reference product, they noted.

Because biosimilars are intended to have no clinically meaningful differences in safety, purity, or potency versus the approved reference drug, understanding the margin of error is “critical” to determine if “potentially clinically important differences in efficacy were ruled out statistically by study design,” the authors commented.

The “quandary” of the margin of error question is compounded by the issue of sample size, according to Wan and co-authors.

In a trial powered at 0.80 with a ±15% margin of error, 382 patients would be needed. However, with a narrower ±10% margin of error, an additional 476 patients would be needed, according to the authors’ calculations.

These and other critical factors not well understood by the average dermatologist include study population variability, study site geography, and clinical expertise, they noted.

Biosimilar studies

Wan and colleagues reported specific data for the four double-blind, randomized, controlled trials that compared biosimilars to reference agents.

In a trial of 350 patients randomized 1:1 to the biosimilar adalimumab-atto or adalimumab, the margin of error was ±15% and the study power was 0.90, authors said. The primary outcome was mean percent improvement in PASI from baseline to week 16. The reported response rate in the trial was 86.6% for the biosimilar versus 88% for the reference drug.

Another trial looked at the biosimilar etanercept-szzs versus etanercept that included 531 patients, the margin of error was ±18% and the study power was 0.90. For the primary outcome of PASI 75 at week 12, the response rate was 70.4% for the biosimilar and 71.6% for the originator drug.

The margin of error was also ±18% in a randomized study of CHS-0214 versus etanercept including 521 patients, but the study power was yet to be determined, authors of the meta-analysis said at the time of their report. The primary outcome was PASI 75 and the response rate was 64.5% and 62.3%, respectively, for CHS-0214 and etanercept.

The final randomized comparative trial, which had a margin of error of ±14% and a study power of 0.80, compared BCD-057 to adalimumab in 344 patients. The primary outcome is PASI 75 at 16 weeks and the response rate has not yet been determined, according to the meta-analysis report.

This article originally appeared on our partner’s website Dermatology Times, which is a part of UBM Medica. (Free registration is required.)

The study’s co-authors reported research funding and other disclosures related to commercial entities including AbbVie, Inc, Amgen, Boehringer Ingelheim, Dermira, Eli Lilly and Company, Janssen Pharmaceutical, Novartis, Regeneron, and Sun Pharmaceutical Industries Ltd, among others. Full disclosures are listed in the Journal.

2018-01-06T10:00:00-0500

Tagged with:

About author

Related Articles